celecoxib has been researched along with benzo(a)pyrene in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arora, N; Koul, A; Tanwar, L | 1 |
Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P | 1 |
2 other study(ies) available for celecoxib and benzo(a)pyrene
Article | Year |
---|---|
Celecoxib administration exhibits tissue specific effect on 3H-benzo(a)pyrene-DNA adduct formation in cigarette smoke inhaling mice.
Topics: Administration, Oral; Animals; Benzo(a)pyrene; Body Weight; Celecoxib; Cytochrome P-450 Enzyme System; Disease Models, Animal; DNA Adducts; Glutathione Transferase; Liver; Lung; Male; Mice; Mice, Inbred BALB C; Pyrazoles; Sulfonamides; Tobacco Smoke Pollution | 2009 |
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Bronchoalveolar Lavage Fluid; Carboplatin; Celecoxib; Cell Count; Collagen; Delayed-Action Preparations; Female; L-Lactate Dehydrogenase; Lactic Acid; Lung Neoplasms; Mice; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pulmonary Fibrosis; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |